Form 4: Veradigm Director Carol Zierhoffer Receives Significant RSU Grant

Veradigm Inc. Director Carol J. Zierhoffer was granted 46,512 Restricted Stock Units (RSUs) on June 2, 2025, increasing her beneficial ownership to 130,892 shares.

Summary

• Carol J. Zierhoffer, a Director of Veradigm Inc. (MDRX), acquired 46,512 shares of Common Stock on June 2, 2025.
• The acquisition was an award of Restricted Stock Units (RSUs) granted under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.
• These RSUs are scheduled to vest 100% on the first anniversary of the grant date, which is June 2, 2026.
• Following this transaction, Ms. Zierhoffer's beneficial ownership of Veradigm Common Stock increased to 130,892 shares.
• The reported price for the acquisition of these RSUs was $4.3 per share, although RSU grants typically have an acquisition price of $0.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive signal, indicating continued alignment of management/director interests with shareholder value and is a standard form of compensation.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with long-term shareholder value, as the value of the grant is tied to the company's stock performance.
• The increase in beneficial ownership by a director demonstrates continued commitment and confidence in the company's future.

Future Outlook

The granted Restricted Stock Units are scheduled to vest on June 2, 2026, indicating a future increase in the director's direct share ownership upon vesting.

Industry Context

Form 4 filings are standard regulatory disclosures for reporting insider transactions. The grant of Restricted Stock Units is a common form of non-cash compensation for directors and executives across various industries, including healthcare IT, designed to align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation mechanism for directors is a widely adopted practice across publicly traded companies, including those in the healthcare technology sector.
• While specific peer compensation data is not provided in this filing, the structure of the RSU grant (vesting over one year) is consistent with common industry practices for director equity awards, aiming to retain talent and align interests with long-term company performance.

Corporate Governance

Related Party Transactions

• The RSU grant to Carol J. Zierhoffer, a director, constitutes a related party transaction, which is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 46,512 Restricted Stock Units are expected to vest on June 2, 2026.

Key Dates

Recommendation

Keywords

Veradigm, MDRX, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU, stock grant, director compensation, beneficial ownership